"Black box" pharmacogenetic decision-support tools in psychiatry
- PMID: 31994639
- PMCID: PMC7115459
- DOI: 10.1590/1516-4446-2019-0724
"Black box" pharmacogenetic decision-support tools in psychiatry
Conflict of interest statement
CAB has received material support from Assurex Health (Myriad Neuroscience), CNSDose, Genomind, and AB-Biotics for research purposes and has ongoing research collaborations with MyDNA, but does not have equity, stocks, or options in these companies or any other pharmacogenetic companies. HAE owns shares in CNSDose Pty Ltd.
Figures
References
-
- Clinical Pharmacogenetics Implementation Consortium . 2019. https://cpicpgx.org [Internet]. [cited Nov 07 2019]
-
- PharmGKB . 2019. http://www.pharmgkb.org [Internet]. [cited Nov 07 2019]
-
- Carey P. Data protection: a practical guide to UK and EU law. 5th ed. Oxford: Oxford University; 2018.
-
- Holm EA. In defense of the black box. Science. 2019;364:26–7. - PubMed
-
- Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources